Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingMay 27, 2026Atomoxetine Capsules HCLLabeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.Safecor Health, LLC · D-0538-2026Class IIIOngoingMay 27, 2026Primidone TabletsCross contamination with other products: API contaminated with trace amounts of Acemetacin API.Amerisource Health Services LLC · D-0537-2026Class IIIOngoingMay 27, 2026Primidone TabletsCross contamination with other products: API contaminated with trace amounts of Acemetacin API.Amerisource Health Services LLC · D-0536-2026Class IIIOngoingMay 27, 2026Primidone TabletsCross contamination with other products: API contaminated with trace amounts of Acemetacin API.Golden State Medical Supply Inc. · D-0535-2026Class IIIOngoingMay 27, 2026Primidone TabletsCross contamination with other products: API contaminated with trace amounts of Acemetacin API.Golden State Medical Supply Inc. · D-0534-2026Class IIIOngoingMay 27, 2026Primidone Tablets USPCross contamination with other products: API contaminated with trace amounts of Acemetacin API.Lannett Company Inc. · D-0533-2026Class IIOngoingMay 20, 2026Ascend LaboratoriesFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0547-2026Class IIOngoingMay 20, 2026Buprenorphine HydrochlorideCrystallization; identified as Buprenorphine free baseENDO USA, Inc. · D-0527-2026Class IIOngoingMay 20, 2026Oasis Tears PFLack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.Oasis Medical, Inc. · D-0525-2026Class IOngoingMay 13, 2026Lactated Ringer's Injection USPPresence of Particulate Matter.B Braun Medical Inc · D-0540-2026Class IIOngoingMay 13, 2026TPN bagIncorrect Product Formulation: product did not contain insulin as listed in the label.Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles · D-0524-2026Class IIOngoingMay 13, 2026NAPROXEN ORAL SUSPENSIONChemical contamination; presence of lead and lithium above specificationAcella Pharmaceuticals, LLC · D-0523-2026Class IIOngoingMay 13, 2026Duloxetine Delayed-Release Capsules USPCGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limitBreckenridge Pharmaceutical, Inc. · D-0522-2026Class IIOngoingMay 13, 2026Enalapril Maleate TabletsFailed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities TestJB Chemicals and Pharmaceuticals Ltd · D-0520-2026Class IIOngoingMay 13, 2026Octreotide Acetate for Injectable SuspensionLack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.Teva Pharmaceuticals USA, Inc · D-0519-2026Class IIOngoingMay 13, 2026BD PurPrepLack of assurance of Sterility: potential product contaminationCareFusion 213, LLC · D-0518-2026Class IIOngoingMay 13, 2026BD PurPrepLack of assurance of Sterility: potential product contaminationCareFusion 213, LLC · D-0517-2026Class IIOngoingMay 13, 2026Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.Ajanta Pharma Ltd. · D-0516-2026Class IIOngoingMay 13, 2026Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.Ajanta Pharma Ltd. · D-0515-2026Class IIOngoingMay 13, 2026Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.Ajanta Pharma Ltd. · D-0514-2026Class IIOngoingMay 13, 2026DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange Set for Intraperitoneal...Lack of Assurance of Sterility: Potential leaks from perforations in bags.Fresenius Medical Care Holdings, Inc. · D-0513-2026Class IIOngoingMay 13, 2026DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange Set for Intraperitoneal...Lack of Assurance of Sterility: Potential leaks from perforations in bags.Fresenius Medical Care Holdings, Inc. · D-0512-2026Class IIIOngoingMay 13, 2026busPIRone Hydrochloride TabletsSubpotent drugUnichem Pharmaceuticals USA Inc. · D-0511-2026Class IIOngoingMay 6, 2026Alendronate Sodium Oral SolutionThis recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.Hikma Pharmaceuticals USA INC · D-0526-2026Class IIIOngoingMay 6, 2026Lidocaine Wound GelFailed PH SpecificationsWater-Jel Technologies, LLC · D-0509-2026Class IIOngoingMay 6, 2026fentaNYL Citrate Injectable Solution in 0.9% Sodium ChloridecGMP deviations.Wells Pharma of Houston LLC · D-0508-2026Class IIOngoingMay 6, 2026Ketamine Hydrochloride Injectable SolutioncGMP deviations.Wells Pharma of Houston LLC · D-0507-2026Class IIOngoingMay 6, 2026fentaNYL Citrate Injectable Solution in 0.9% Sodium ChloridecGMP deviations.Wells Pharma of Houston LLC · D-0506-2026Class IIOngoingMay 6, 2026fentaNYL Citrate Injectable SolutioncGMP deviations.Wells Pharma of Houston LLC · D-0505-2026Class IIOngoingMay 6, 2026fentaNYL Citrate injectable Solution in 0.9% Sodium ChloridecGMP deviations.Wells Pharma of Houston LLC · D-0504-2026Class IIOngoingMay 6, 2026fentaNYL Citrate Injectable SolutioncGMP deviations.Wells Pharma of Houston LLC · D-0503-2026Class IIOngoingMay 6, 2026Phenylephrine Hydrochloride Injectable SolutioncGMP deviations.Wells Pharma of Houston LLC · D-0502-2026Class IIOngoingMay 6, 2026SimilasanLack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.Thea Pharma, Inc. · D-0501-2026Class IIOngoingMay 6, 2026iVIZIA, Sterile Lubricant Eye DropsLack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.Thea Pharma, Inc. · D-0500-2026Class IIOngoingMay 6, 2026Optase Dry Eye Intense DropsLack of Assurance of SterilityScope Health · D-0499-2026Class IIIOngoingMay 6, 2026Levocarnitine InjectionLabeling: Missing LabelAmerican Regent, Inc. · D-0494-2026Class IIOngoingMay 6, 2026GenTeal TearsLack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.Alcon Research LLC · D-0492-2026Class IIOngoingMay 6, 2026Systane, Lubricant Eye GelLack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.Alcon Research LLC · D-0491-2026Class IIOngoingApr 29, 2026ClaravisFailed Impurities/Degradation Specifications: Out of specification for specific impurity TretinoinTeva Pharmaceuticals USA, Inc · D-0521-2026Class IIOngoingApr 29, 2026LACTATED RINGER'S IRRIGATIONLack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.B Braun Medical Inc · D-0498-2026

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.